AKTX
Akari Therapeutics, Plc NASDAQ Listed Jan 6, 2014$10.41
+1.56%
vs $10.25
Mkt Cap $8.8M
52w Low $3.06
16.8% of range
52w High $46.80
50d MA $9.82
200d MA $15.06
P/E (TTM)
-0.0x
EV/EBITDA
—
P/B
0.3x
Debt/Equity
0.0x
ROE
-61.1%
P/FCF
-0.8x
RSI (14)
27.90
ATR (14)
$1.67
Beta
0.54
50d MA
$9.82
200d MA
$15.06
Avg Volume
1.6M
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
75/76 Wimpole Street · London, FL W1G 9RT · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7, 2026 | AMC | -1.80 | -2.99 | -66.1% | 3.80 | -0.5% | +2.1% | +1.0% | -2.3% | +11.0% | +8.9% | — |
| Nov 13, 2025 | AMC | -0.04 | -0.10 | -150.0% | 20.80 | +7.7% | +1.7% | -10.4% | +12.0% | -6.0% | -7.3% | — |
| Aug 13, 2025 | AMC | -0.09 | -0.06 | +33.3% | 39.30 | +1.8% | -1.3% | +4.1% | -1.0% | -0.9% | -4.2% | — |
| May 14, 2025 | AMC | — | -0.14 | — | 54.00 | -3.7% | -2.2% | -3.8% | -0.8% | +3.2% | -4.6% | — |
| Apr 14, 2025 | AMC | -1.00 | -0.17 | +83.0% | 44.40 | +14.4% | +8.1% | -8.3% | +10.0% | +5.8% | +6.2% | — |
| Nov 19, 2024 | AMC | -0.60 | -9.60 | -1500.0% | 62.80 | +7.0% | -6.4% | -15.6% | +4.8% | -20.8% | +10.7% | — |
| Aug 19, 2024 | AMC | -1.00 | -3.20 | -220.0% | 144.00 | -6.4% | -0.3% | +0.0% | +3.3% | +3.5% | -1.0% | — |
| May 15, 2024 | AMC | -1.00 | -3.20 | -220.0% | 58.40 | -1.4% | +1.4% | +2.7% | +0.0% | +7.9% | +16.5% | — |
| Mar 29, 2024 | AMC | — | -2.40 | — | — | — | — | — | — | — | — | — |
| Oct 3, 2023 | AMC | -0.60 | -2.40 | -300.0% | 153.60 | -4.9% | -5.2% | +0.0% | +1.7% | -0.9% | -2.7% | — |
| Sep 26, 2023 | AMC | -1.00 | 2.00 | +300.0% | 162.00 | -6.9% | +0.0% | +0.7% | -3.2% | -8.6% | +6.3% | — |
| Jul 19, 2023 | AMC | -0.07 | -0.10 | -42.9% | 140.80 | -1.7% | -0.6% | -0.6% | +0.0% | +8.0% | +4.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8 | Maxim Group | Downgrade | Buy → Hold | — | $3.80 | $3.78 | -0.5% | +2.1% | +1.0% | -2.3% | +11.0% | +8.9% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.15 | $5.15 | +0.0% | -9.7% | -3.9% | -20.8% | +7.3% | +2.1% |
| Sep 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.00 | $35.44 | +4.2% | -1.2% | -6.0% | -2.5% | +2.5% | -1.7% |
| Dec 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $431.20 | $460.00 | +6.7% | +3.7% | -3.4% | +5.6% | -7.0% | -0.8% |
| Nov 1 | Alliance Global Partners | Maintains | Buy → Buy | — | $372.80 | $380.00 | +1.9% | +1.1% | +4.0% | +0.0% | -0.4% | +0.4% |
| Mar 13 | B. Riley FBR | Maintains | Buy → Buy | — | $1104.00 | $1128.00 | +2.2% | -8.7% | -15.9% | +18.9% | -2.1% | +2.8% |
| Mar 13 | B. Riley Securities | Maintains | Buy → Buy | — | $1104.00 | $1128.00 | +2.2% | -8.7% | -15.9% | +18.9% | -2.1% | +2.8% |
| Mar 12 | B. Riley Securities | Maintains | Buy → Buy | — | $1233.60 | $1200.00 | -2.7% | -10.5% | -8.7% | -15.9% | +18.9% | -2.1% |
| May 5 | B. Riley FBR | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Mar 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $1416.00 | $1408.00 | -0.6% | +2.8% | +1.1% | -2.2% | +0.0% | +9.4% |
| Feb 8 | B. Riley FBR | Maintains | Neutral → Neutral | — | $1752.00 | $1760.00 | +0.5% | +4.6% | +1.3% | +9.9% | -5.5% | +0.4% |
| Sep 22 | William Blair | Upgrade | Market Perform → Outperform | — | $6992.00 | $7864.00 | +12.5% | -6.4% | -11.0% | -2.3% | -3.4% | -8.2% |
| May 31 | Chardan Capital | Upgrade | Sell → Neutral | — | $4712.00 | $4920.00 | +4.4% | +4.1% | +1.6% | +7.9% | -9.5% | -1.5% |
| May 12 | William Blair | Downgrade | Outperform → Market Perform | — | $9192.00 | $7440.00 | -19.1% | -21.4% | +0.9% | -11.4% | -4.8% | -3.4% |
| May 11 | William Blair | Downgrade | Outperform → Perform | — | $8800.00 | $8944.00 | +1.6% | +4.5% | -21.4% | +0.9% | -11.4% | -4.8% |
| Apr 17 | Chardan Capital | Maintains | Sell → Sell | — | $12816.00 | $12088.00 | -5.7% | -16.9% | +12.5% | -7.9% | +18.7% | +25.2% |
| Jul 11 | Chardan Capital | Maintains | Sell → Sell | — | $9623.20 | $8800.00 | -8.6% | -8.1% | +1.4% | +3.6% | -3.2% | -12.7% |
No insider trades available.
8-K
Akari Therapeutics, Plc -- 8-K Filing
Jul 2
8-K
Akari Therapeutics, Plc -- 8-K Filing
Jun 26
NT 10-Q
!! High
Akari Therapeutics, Plc -- Late Quarterly Report -- Distress Signal
May 18
8-K
Akari Therapeutics plc ADR (0.01 USD) -- 8-K Filing
Akari Therapeutics completed private placement financings in December 2025 and January 2026, securing capital to fund operations and development initiatives.
Mar 2
Institutional (13F) — Top 1
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Ifp Advisors, Inc | 181 | $932 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$8.8M
Enterprise Value
$3.6M
P/E (TTM)
-0.01x
Forward P/E
—
PEG Ratio
0.00x
P/B
0.31x
P/S
—
P/FCF
-0.83x
EV/EBITDA
—
Shares Out
842K
Financials (TTM)
Revenue
$0
Net Income
-$28.0M
EBITDA
-$29.0M
Free Cash Flow
-$10.6M
Op Cash Flow
-$10.6M
EPS Basic
$-20800.00
EPS Diluted
$-1448.00
EPS Forward
$-5.77
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$47.9M
Total Liab.
$19.6M
Total Equity
$28.3M
Cash
$5.2M
LT Debt
$0
Book Value/Sh
$33.66
Debt/Equity
0.03x
Current Ratio
0.44
Quick Ratio
0.44
Returns & Growth
ROE
-61.1%
ROA
-36.1%
ROIC
-45.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
-32400.0%
Price Returns
2W
-13.2%
1M
-30.6%
3M
+194.1%
6M
-10.3%
12M
-77.8%
Technicals
52W High
$46.80
52W Low
$3.06
50d MA
$9.82
200d MA
$15.06
RSI (14)
27.90
ATR (14)
$1.67
Beta
0.54
Avg Volume
1.6M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$1200.00
High
$1200.00
Low
$1200.00
Median
$1200.00
Data updated apr 26, 2026 9:31am
· Source: financialmodelingprep.com